Related Experiment Videos
[Monotherapy with clodronate for tumor-induced hypercalcemia]
Deutsche Medizinische Wochenschrift (1946)
|January 12, 1990
Summary
Clodronate effectively treats tumor-induced hypercalcaemia, significantly lowering serum calcium levels within days. This bisphosphonate is recommended for standard treatment with minimal side effects.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Context:
- Tumor-induced hypercalcaemia is a serious complication of various cancers.
- Effective management of hypercalcaemia is crucial for patient well-being and treatment tolerance.
Purpose:
- To evaluate the efficacy and safety of daily clodronate in treating tumor-induced hypercalcaemia.
Summary:
- A phase II study involved 15 patients with cancer-induced hypercalcaemia treated with 300 mg of clodronate daily.
- Serum calcium levels decreased significantly within two days, with hypercalcaemia resolved in 15 out of 16 episodes after a mean of 4.3 days.
- Treatment was ineffective in one case of paraneoplastic hypercalcaemia.
Impact:
- Clodronate demonstrates significant efficacy in managing tumor-induced hypercalcaemia.
- The medication is well-tolerated with minimal side effects.
- Results suggest clodronate should be considered a standard treatment for this condition.